- Policy
- CSOs entrusted to companies are pursuing expenditure reports
- by Kim, Jung-Ju Dec 17, 2020 06:11am
- Amendments to the law will be promoted to mandate expenditure reports related to the provision of economic benefits, etc., submitted by entrusted CSOs to the government. Chun Sook Jung, a member of Democratic Party of Korea representatively proposed a partial amendment to the Pharmaceutical Affairs Act. According to the current law, drug s
- Policy
- AZ vaccine is expected to be supplied in Korea the fastest
- by Kim, Jung-Ju Dec 16, 2020 06:14am
- With the spread of COVID-19 in Korea again growing, the quarantine authorities are negotiating on the premise of completing contracts for two products of the overseas COVID-19 vaccine within at least this month. Authorities predicted that the AstraZeneca product would be introduced to Korea the fastest. Jeong Eun-kyeong, head of the Cen
- Policy
- Will special imports be applied for vaccine introduction?
- by Lee, Tak-Sun Dec 15, 2020 06:04am
- Public opinion is growing as the number of COVID-19 confirmed cases is recording the highest every day, and the FDA also urgently approves Pfizer's mRNA-based COVID-19 vaccine following the first vaccination in the UK. Some criticized Korea for failing to preemptively secure a vaccine unlike other advanced countries. It takes some time to
- Policy
- MOHW “Not to worry vaccine shortage, delay and safety”
- by Lee, Jeong-Hwan Dec 15, 2020 06:03am
- The South Korea’s Ministry of Health and Welfare (MOHW) official says the concerns about the shortage or delay in COVID-19 vaccine distribution or AstraZeneca vaccine’s safety issue would be unnecessary. The official claimed the government has already secured vaccine doses for total 44 million people through COVAX Facility and privat
- Policy
- The vaccination fee for COVID-19 will be free
- by Kang, Shin-Kook Dec 14, 2020 05:57am
- The vaccination fee is free in principle, and the elderly and medical staff will be given priority. IT starts from February to March next year as early as possible. The inoculation rate of 60-70% for the nation to become immune is expected to reach the second half of next year. Young-Rae Son, Central Disaster Management Headquarters' plann
- Policy
- HIRA green lit coverage on 14 out of 26 new drugs
- by Lee, Hye-Kyung Dec 10, 2020 06:11am
- 14 out of 26 new drugs deliberated by the Health Insurance Review and Assessment Service (HIRA) Drug Reimbursement Evaluation Committee (DREC) were listed for the healthcare reimbursement. To this date, the DREC has listing rate of 53.8%, but it could get higher as there are new drugs, cleared by DREC during the 10th meeting convened i
- Policy
- Secured COVID-19 vaccines for 44 million people
- by Lee, Tak-Sun Dec 10, 2020 06:09am
- The government announced that it has secured up to COVID-19 vaccines for 44 million people AstraZeneca, a global pharmaceutical company, has already signed a contract to supply 10 million vaccines (20 million doses), and Pfizer and Modena announced that they have signed a binding purchase agreement with 10 million doses (20 million doses) re
- Policy
- Clinical data for COVID-19 vaccine will be submitted soon
- by Lee, Tak-Sun Dec 9, 2020 05:56am
- Minister of Health and Welfare Park Neung-hoo said that AstraZeneca will soon submit clinical trial data for COVID-19 vaccine to the MFDS. On the morning of the 8th, the government announced that it has signed a purchase contract with AstraZeneca for 10 million COVID-19 vaccines. In a press briefing after the announcement, Minister Park s
- Policy
- Drug price negotiation agreement by NHIS is 97.9%
- by Lee, Hye-Kyung Dec 8, 2020 06:12am
- 285 items (97.9%) completed drug price negotiations. Dailypharm reviewed the current status of drug price negotiations on December 29, 2006, after the last health insurance registration method was switched to the positive list system as part of a plan to optimize drug costs. Negotiations were completed for 1,924 items out of a total of 1972 n
- Policy
- Xultophy Flex Touch pen·Afstyla can be reimbursed
- by Lee, Hye-Kyung Dec 8, 2020 06:11am
- Novo Nordisk's Xultophy Flex Touch pen (Insulin Degludec and Liraglutide) and CSL Behring's Afstyla (Antihemophilic Factor) were set higher in the amount applied by pharmaceutical companies compared to the adequacy evaluation of Benefits. The HIRA (President Kim Sun-min) released the results of the deliberation on the adequacy of medical
